Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nt plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which was filed with the SEC on May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

(1) American Cancer Society, Cancer Facts and Figures 2008


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Bruin Biometrics (BBI), a pioneer in biometric-sensor ... weeks of clinical briefings to over 200 pressure ... substantial concurrence on both the clinical validity of ... BBI,s SEM Scanner. "From our ... drawn from the European Wound Management Association (EWMA) ...
(Date:7/24/2014)... July 24, 2014  Bayer HealthCare today announced ... evaluated a 15% foam formulation of its compound ... inflammatory papules and pustules of rosacea. An AzA ... complement the currently available AzA gel formulation. Papulopustular ... (papules and pustules) as well as erythema (redness) ...
(Date:7/24/2014)... , July 24, 2014  Market Diagnostics ... IVD Insights™ LabFile , a data resource ... US clinical laboratory universe and identifying target In ... a proprietary database that provides IVD manufacturers with ... tests, relying on clear and consistent definitions of ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 2Phase III Investigational Trial of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints in Subjects with Papulopustular Rosacea 3MDxI Launches Data Resource Setting New Standard for Defining and Targeting US Clinical Laboratory Universe 2
... June 18, 2007 /PRNewswire/ -- Today, results,from ... comparing two angiotensin,receptor blockers (ARBs) in hypertensive ... 17th annual European Meeting on,Hypertension in Milan, ... parallel group,multicenter study included 860 hypertensive patients,(>130/80mmHg) ...
... 2007 --- Millipore Corporation today announced the release ... lines. The,research was conducted by the Department ... plc, whose ReNcell,distribution agreement with Millipore was announced ... Dr. Vi Chu, research &,development scientist for Millipore’s ...
Cached Medicine Technology:New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes 2New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes 3New Data Presented on Micardis (Telmisartan) Tablets in,Hypertensive Patients With Type 2 Diabetes 4Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 2Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 3Millipore Corporation Announces New ReNcell Data from Collaboration,with ReNeuron 4
(Date:7/24/2014)... The North American air and missile defense ... and is expected to register a CAGR of 8.22% to ... biggest market for the air and missile defense radar system. ... witnessed budget cuts as well. , Browse through the TOC ... report, to get an idea of the in-depth analysis provided. ...
(Date:7/24/2014)... -- Even though its use is often advised by doctors, ... not help treat lower back pain, according to a new ... no more effective than a dummy pill for more than ... showing no effect in easing discomfort, the study also found ... to back pain, nor did it improve patients, overall quality ...
(Date:7/24/2014)... emergency departments can be reduced by enabling patients to ... doctor,s surgery. This is just one of several recommendations ... at the University of Bristol. , Called ,Primary care ... reviews, the report has been compiled by researchers from ... at evidence from studies around the world. They found ...
(Date:7/24/2014)... have identified two previously undescribed radiological signs ... gastric bands. Adding widespread knowledge of the ... margin by more than 2.4 cm from ... air-fluid,level above the band on a frontal ... in diagnosing affected bariatric patients. These signs ...
(Date:7/24/2014)... neonicotinoids, were found commonly in streams throughout the ... is the first broad-scale investigation of neonicotinoid insecticides ... the first conducted within the United States. , ... pests, use of neonicotinoid insecticides has dramatically increased ... particularly in the Midwest. The use of ...
Breaking Medicine News(10 mins):Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2
... a twin are at upto 5 times higher risk of suffering ... was conducted on over 800 pairs of twins in the UK ... age of 40 was 3-5 times higher in twins than women ... ten years or earlier than the usual period. Only 1-in-100 women ...
... The diagnosis of Kylie Minogue with breast cancer has led to ... get breast cancer//. ,Cancer Research UK said that ... strike the under-70s than women over 70,. ,Their survey ... that a woman's risk of breast cancer was increased if she ...
... toddlers, reports a major study conducted on the side effects of ... proposed immunization for all kids of the age 6 months to ... sharp rise in the number of children getting vaccinated. This proposal ... years as often as the old people. ,This study ...
... A 1-year-old girl has been diagnosed with polio in spite ... an official statement, polio can be prevented by 4-10 doses ... this girl called Jannat. ,“Earlier she used to ... Jannat's Mother, Akhbari Khatun says.,Jannat was diagnosed with polio just ...
... from heart surgery. A Researcher from the University of Calary has ... Kathryn King, in her research informs that those who wore ... and discomfort, when compared those who were in a ... to the Canadian Cardiovascular Congress in Vancouver after two years of ...
... A recent research proposes that radiations from handsets may affect fertility ... count than normal.// ,A study conducted on 361 ... the daily mobile use by the man, there was a decrease ... a 40% reduction in sperm count in men who used mobile ...
Cached Medicine News:Health News:Mobile use increases risk of infertility in men 2
1 mm wide by 28 mm long sterling silver blade. Flat serrated handle with polished finish....
Double ended lasik spatula with flattened tip for lifting and smoothing the corneal flap. The sharp tip is useful to outline a previous flap in preparation for retreatment....
Serrated rake tip spatula with 20 gauge shaft. Black finish for reduced glare. Can be used with 20 gauge MVR blades....
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Medicine Products: